1. Home
  2. BDSX vs KZIA Comparison

BDSX vs KZIA Comparison

Compare BDSX & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biodesix Inc.

BDSX

Biodesix Inc.

HOLD

Current Price

$16.43

Market Cap

122.0M

Sector

Health Care

ML Signal

HOLD

Logo Kazia Therapeutics Limited

KZIA

Kazia Therapeutics Limited

HOLD

Current Price

$7.81

Market Cap

93.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BDSX
KZIA
Founded
2005
1994
Country
United States
Australia
Employees
N/A
N/A
Industry
Precision Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
122.0M
93.2M
IPO Year
2020
2002

Fundamental Metrics

Financial Performance
Metric
BDSX
KZIA
Price
$16.43
$7.81
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
3
Target Price
$32.50
$17.67
AVG Volume (30 Days)
139.9K
182.7K
Earning Date
05-21-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$88,499,000.00
N/A
Revenue This Year
$23.35
N/A
Revenue Next Year
$19.33
N/A
P/E Ratio
N/A
N/A
Revenue Growth
24.08
N/A
52 Week Low
$0.25
$0.64
52 Week High
$20.21
$17.40

Technical Indicators

Market Signals
Indicator
BDSX
KZIA
Relative Strength Index (RSI) 57.36 50.80
Support Level $6.33 $7.54
Resistance Level N/A $8.17
Average True Range (ATR) 1.91 1.13
MACD -0.10 -0.08
Stochastic Oscillator 53.31 19.91

Price Performance

Historical Comparison
BDSX
KZIA

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

Share on Social Networks: